Clinical Scorecard: Risk Assessment for Hepatocellular Carcinoma in Viral Hepatitis Patients: The SELECT Scoring System for Enhanced Surveillance

At a Glance

Key Highlights

• HCC accounts for 75–85% of primary liver cancers and is a leading cause of cancer mortality due to late diagnosis.
• Ultrasound has suboptimal sensitivity for early HCC detection; alternative imaging is costly and should be targeted to high-risk patients.
• The SELECT scoring system incorporates ultrasound features with clinical and laboratory data to stratify HCC risk and guide intensive surveillance.

Guideline-Based Recommendations

Diagnosis

• Perform biannual ultrasound surveillance in patients with chronic hepatitis B or C aged 40-75 years.
• Assess ultrasound features including liver echotexture, hepatic steatosis, cirrhotic nodules, ascites, and splenomegaly.
• Use serologic tests (CBC, liver function tests, AFP) within 8 weeks of ultrasound to complement risk assessment.

Management

• Identify high-risk patients using the SELECT scoring system to selectively apply intensive surveillance with alternative imaging modalities.
• Exclude patients with prior HCC, advanced liver disease (Child-Pugh B or C), or incomplete data from intensive surveillance eligibility.

Monitoring & Follow-up

• Conduct follow-up surveillance at least annually for at least one year after index ultrasound.
• Monitor clinical visits, antiviral medication use, and development of HCC during follow-up.

Risks

• Advanced liver disease and prior HCC diagnosis are exclusion criteria due to altered risk profiles.
• Suboptimal sensitivity of ultrasound alone may delay early HCC detection in some patients.

Patient & Prescribing Data

Patients with chronic hepatitis B or C aged 40-75 years undergoing HCC surveillance

Use of antiviral medications and clinical parameters are recorded but not directly integrated into the SELECT scoring system; antiviral therapy status should be considered in comprehensive management.

Clinical Best Practices

• Apply the SELECT scoring system to combine ultrasound imaging features with clinical and laboratory data for accurate HCC risk stratification.
• Use established cut-offs to categorize patients into low-, intermediate-, and high-risk groups to optimize surveillance intensity.
• Ensure consistent and standardized ultrasound reporting to improve inter-observer agreement and model reliability.
• Select patients with an estimated annual HCC incidence ≥ 2.5% for intensive surveillance using alternative imaging modalities to improve diagnostic yield and cost-effectiveness.

References

• Primary liver cancer statistics and surveillance recommendations
• Ultrasound sensitivity limitations in early HCC detection
• HCC risk prediction models and scoring systems
• Inter-observer agreement in ultrasound feature assessment